---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-078451"
form_type: "8-K"
ticker: "CARM"
cik: "0001485003"
company_name: "Carisma Therapeutics Inc."
filed_at: "2024-07-09T23:59:59+00:00"
generated_at: "2026-05-31T22:34:20.449144+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Carisma reports 75% ctDNA reduction in HER2 3+ patients in Phase 1 CT-0508 trial

## Summary
- 75% (6/8) evaluable HER2 3+ patients had ctDNA reduction (median 81%, range 33%-93%); no reduction in 5 HER2 2+ patients.
- Best overall response: stable disease in 44% (4/9) of HER2 3+ patients; all HER2 2+ patients had progressive disease.
- Phase 1 CT-0508 enrollment halted April 2024; all patient activities completed as of July 2024.
- Company expects clinical data updates in Q3 2024 and initial Phase 1 data for follow-on CT-0525 in Q4 2024.
- Preliminary data supports mechanism of action and potential for repeat dosing with CT-0525 in HER2 overexpressing cancers.

## SEC filing metadata
- accession: 0001104659-24-078451
- form_type: 8-K
- ticker: CARM
- cik: 0001485003
- company_name: Carisma Therapeutics Inc.
- filed_at: 2024-07-09T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1485003/000110465924078451/0001104659-24-078451-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1485003/000110465924078451/tm2419051d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-078451
- JSON: https://secwatch.observer/filing/0001104659-24-078451.json
- Plain text: https://secwatch.observer/filing/0001104659-24-078451.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.